Roche Presents Real-World Evidence for Vabysmo in Diabetic Macular Edema

Roche today presented real-world evidence from multiple healthcare systems showing that Vabysmo (faricimab-svoa) maintains significant vision improvements with extended dosing intervals in patients with diabetic macular edema (DME). The data showed that approximately 60% of patients achieved dosing intervals of 12 weeks or longer after the initial loading phase.